|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006141,
umls-concept:C0183683,
umls-concept:C0210630,
umls-concept:C0344211,
umls-concept:C0585332,
umls-concept:C0684249,
umls-concept:C0920321,
umls-concept:C1171411,
umls-concept:C1317973,
umls-concept:C1516213,
umls-concept:C1521721
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2003-12-5
|
|
pubmed:abstractText |
Docetaxel (DTX) has been shown to be a very active drug in both breast cancer (BC) and non-small-cell lung cancer (NSCLC). Irinotecan (CPT-11) is also active in NSCLC, and has shown promising antitumor activity in pretreated BC. PURPOSE. To define the MTDs of these two drugs given together every other week with the use of filgrastim support in pretreated BC and NSCLC patients.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0344-5704
|
|
pubmed:author |
pubmed-author:BottiGerardoG,
pubmed-author:CapassoImmacolataI,
pubmed-author:ComellaGiuseppeG,
pubmed-author:ComellaPasqualeP,
pubmed-author:D'AiutoGiuseppeG,
pubmed-author:De RosaVincenzoV,
pubmed-author:Di BonitoMaurizioM,
pubmed-author:FrasciGiuseppeG,
pubmed-author:LapentaLilianaL,
pubmed-author:ThomasRenatoR,
pubmed-author:VallonePaoloP
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
53
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
25-32
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:14513281-Adult,
pubmed-meshheading:14513281-Aged,
pubmed-meshheading:14513281-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:14513281-Breast Neoplasms,
pubmed-meshheading:14513281-Camptothecin,
pubmed-meshheading:14513281-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:14513281-Disease-Free Survival,
pubmed-meshheading:14513281-Dose-Response Relationship, Drug,
pubmed-meshheading:14513281-Drug Administration Schedule,
pubmed-meshheading:14513281-Female,
pubmed-meshheading:14513281-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:14513281-Humans,
pubmed-meshheading:14513281-Lung Neoplasms,
pubmed-meshheading:14513281-Male,
pubmed-meshheading:14513281-Maximum Tolerated Dose,
pubmed-meshheading:14513281-Middle Aged,
pubmed-meshheading:14513281-Neoplasm Metastasis,
pubmed-meshheading:14513281-Neoplasm Staging,
pubmed-meshheading:14513281-Recombinant Proteins,
pubmed-meshheading:14513281-Taxoids
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Biweekly docetaxel-irinotecan with filgrastim support in pretreated breast and non-small-cell lung cancer patients. A phase I study.
|
|
pubmed:affiliation |
SICOG, c/o National Tumor Institute, Via M Semmola 80131 Naples, Italy. giuseppe.frasci@hbero.it
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase I
|
